Dr. Gina Torres Zambrano publish an article over the Stem cell nebulization therapy for COVID19 infection
Stem cell treatment researches have revealed new frontiers in regenerative medicine, and in times of pandemic, its contribution is reflected in this first article, which our member, urologist Dr. Gina Torres has shared with us, demonstrating the effectiveness of these therapies for the challenges of the present and the future.
Background: SARS-CoV-2 is a highly contagious virus that spread worldwide with a rapid increase in the number of deaths. In March 2020, the WHO declared SARS-CoV-2 a pandemic. The primary diagnostic test is reverse transcription-polymerase chain reaction, but chest X-ray and computed tomography have become the typical diagnostic tools used to detect abnormal lung changes. Within the framework of the SENTAD COVID Study clinical trial, an observational and analytical study was conducted, where the patients received nebulization therapy with the use of autologous stem cells (group A) compared to the control arm (group B). Both groups received the UAE SARS-CoV-2 standard management. Radiological images of each patient were collected within 24 h of inclusion in the trial and during follow-up. Herein, we describe and evaluate the radiological findings and outcomes.
Results: A total of 139 subjects were included in our analysis, 69 in group A and 70 in group B. The most common finding was ground glass opacifications, followed by patchy consolidations, with 20% normal radiological images scored 3 from admission until discharge (p < 0.0001). Our results suggest a significant improvement in radiological images after treatment secondary to the stem cell effect of reducing inflammation and stimulating the pneumological healing process.
Conclusions: The use of novel therapies, such as stem cells, shows efficacy not only in terms of the control of clinical and paraclinical signs but also in the radiological changes described in the disease. Trial registration: Study evaluating the safety and efficacy of autologous non-hematopoietic peripheral blood stem cells in COVID-19.
Trial registration number: NCT04473170. Date of registration: 16 July 20202. Retrospectively registered.
Read more at: https://link.springer.com/epdf/10.1186/s43055-021-00492-3
Comments are closed